Proton pump inhibitors and clopidogrel

Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009 301(9) 934-944. 

Howard PA, Vacek JL. Potential interaction between clopidogrel and proton pump inhibitors. Am J Cardiovasc Drugs 2009 9(6) 353-9. 

Rassen JA, Choudhry NK, Avom J, Schneeweiss S. Cardiovascular outcomes and mortahty in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation2009 120(23) 2322-9. 

Nakayama A, Morita H, Ando J, Fujita H, Ohtsu H, Nagai R. Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or tidopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention. Heart Vessels 2013 28(3) 292-300. 

Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 180(7) 713—718. 

In a separate study in 39 healthy volunteers the interaction of the CYP2C19 genotype and the effect of three proton pump inhibitors (omeprazole 20mg/day, lansoprazole 30 mg/day, and rabeprazole 20 mg/ day for 7 days) on the antiplatelet effect of clopidogrel 75 mg were studied [63 ]. The three proton pump inhibitors affected the efficacy of clopidogrel to different... 

Proton pump inhibitors A systematic review of the evidence has suggested that omeprazole reduces the antiplatelet effects of clopidogrel, probably by competitive inhibition of CYP2C19, that the interaction is clinically significant, and that it may not be shared by other proton pump inhibitors [17SM] reviewers have concluded... 

In a nested case-control study of 734 patients aged 66 years or older who were given clopidogrel following an acute myocardial infarction and had a second admission within 90 days, and 2057 controls, current use of proton pump inhibitors was associated with an increased risk of reinfarction (adjusted OR = 1.27 95% Cl = 1.03, 1.57) [181 j. In a stratified analysis, pantoprazole, which does not inhibit CYP2C19, was not associated with readmis-sion for myocardial infarction (adjusted OR = 1.02 95% a = 0.70,1.47). 

Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 2009 43(7) 1266-74. 

O Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor an analysis of two randomised trials. Lancet 2009 374(9694) 989-97. 

Tsantes AE, Dconomidis I, Papadakis I, Bonovas S, Gialeraki A, Kottaridi C, et al. Impact of the proton pump inhibitors and CYP2C19 2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays. Thromb Res 2013 132(2) el05-11. 

---